Literature DB >> 19855432

Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species.

J-J Lee1, J-H Lee, Y-G Ko, S I Hong, J-S Lee.   

Abstract

Premature senescence is considered as a cellular defense mechanism to prevent tumorigenesis. Although recent evidences show that c-Jun N-terminal kinase (JNK) is involved in the senescence process, the mechanism for this regulation is not fully understood. Here, we examined the role of JNK in premature senescence of tumor cells. Treatment of cells with the JNK-specific inhibitor SP600125 caused phenotypical changes of senescence and triggered a rapid increase in mitochondrial reactive oxygen species (ROS) production and DNA-damage response (DDR) in MCF7 breast carcinoma cells. ROS generation was attributed to the suppression of B-cell lymphoma-2 (Bcl-2) phosphorylation, and resulted in DNA damage and p53 activation. Bax did not change their localization to the mitochondria, which is required for apoptosis. The essential roles of JNK and phosphorylated Bcl-2 in preventing premature senescence were confirmed using RNA interference and ectopic expression of mutants of Bcl-2, including phosphomimetic and nonphosphorylatable forms. These findings were evidenced in H460 lung carcinoma cells and primary human embryonic fibroblasts. Altogether, our results showed that loss of JNK activity triggers a Bcl-2/ROS/DDR signaling cascade that ultimately leads to premature senescence, indicating that basal JNK activity is essential in preventing premature senescence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19855432     DOI: 10.1038/onc.2009.355

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

1.  PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.

Authors:  J-J Lee; B C Kim; M-J Park; Y-S Lee; Y-N Kim; B L Lee; J-S Lee
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 2.  Network Motifs in JNK Signaling.

Authors:  Vasudha Sehgal; Prahlad T Ram
Journal:  Genes Cancer       Date:  2013-09

3.  Reply.

Authors:  Richard F Loeser; John A Collins; Brian O Diekman; Cathy S Carlson
Journal:  Arthritis Rheumatol       Date:  2020-09-30       Impact factor: 10.995

4.  Selective inhibition of mitochondrial JNK signaling achieved using peptide mimicry of the Sab kinase interacting motif-1 (KIM1).

Authors:  Jeremy W Chambers; Lisa Cherry; John D Laughlin; Mariana Figuera-Losada; Philip V Lograsso
Journal:  ACS Chem Biol       Date:  2011-05-24       Impact factor: 5.100

5.  Initiation of premature senescence by Bcl-2 in hypoxic condition.

Authors:  Wei Wang; Desheng Wang; Hong Li
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

6.  JNK Pathway as a Target for Osteoarthritis: Comment on the Article by Loeser et al.

Authors:  Wang-Dong Xu; An-Fang Huang
Journal:  Arthritis Rheumatol       Date:  2020-10-06       Impact factor: 10.995

Review 7.  Regulation of senescence traits by MAPKs.

Authors:  Carlos Anerillas; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Geroscience       Date:  2020-04-16       Impact factor: 7.713

8.  Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration.

Authors:  Jing Xu; Danhong Zhu; Shikun He; Christine Spee; Stephen J Ryan; David R Hinton
Journal:  FASEB J       Date:  2011-03-16       Impact factor: 5.191

9.  Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation.

Authors:  Jeremy W Chambers; Philip V LoGrasso
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

10.  Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer.

Authors:  B Turner-Ivey; Y Manevich; J Schulte; E Kistner-Griffin; A Jezierska-Drutel; Y Liu; C A Neumann
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.